Hospital Infection Therapeutics Market: Industry Analysis and forecast 2026: By Drugs Type, Application and Region

Hospital Infection Therapeutics Market: Industry Analysis and forecast 2026: By Drugs Type, Application and Region

Market Scenario

Hospital Infection Therapeutics Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026. Hospital Infection Therapeutics Market Hospital Infection Therapeutics Market Drivers and Restrains: Hospital-acquired infections are highly dominant adverse events in the health care industry and one of the leading cause of death across the world. Lack of knowledge about the blood transfusion safety measures, understaffing, insufficient hospital equipment and poor infrastructure particularly seen in the emerging and underdeveloped nations are some of the factors responsible for increasing hospital infection, which in turn increases the hospital infection therapeutics market. The hospital infection therapeutics market is driven by factors like an increase in the geriatric population, significant patient population in developing countries demanding proper treatment, and investments by public and private companies for R&D on anti-infective drugs against resistant bacteria. According to the Centers for Disease Control and Prevention (CDC), X out of every XX hospital admitted patient gets contracted with HAIs. Moreover, in the U.S., around XX hospitalized patients died from hospital-acquired infections. However, a surge in the incidence of treatment-emergent resistance, significant investment required due to high attrition rate in clinical trials, and changing reimbursement policies are resulting in limited pipeline drugs are hampering the market growth at the global level. Investment in R&D on non-antibiotic treatment options and partnerships for co-development and commercialization of anti-infective agents are likely to create lucrative opportunities in the hospital infection therapeutics market. Hospital Infection Therapeutics Market Segmentation Analysis: Based on drugs type, the hospital infection therapeutics market has been segmented into Antibiotics Drugs, Antifungal Drugs, and Antiviral Drugs. The antibacterial drugs segment accounted for dominant market share in 2018, owing to an increase in initiatives such as the global action plan on antimicrobial resistance by WHO and Drive AB by Innovative Medicines Initiative, and the presence of key companies involved in the manufacture of anti-bacterial drugs. The relatively stable growth rate of the segment is credited to the rise in antibiotic resistance of bacteria and limited pipeline drug candidates. The anti-viral drugs segment is expected to grow at the largest CAGR of XX% during the forecast period, owing to a rise in the prevalence of severe bloodstream infections and rise in focus on research and development to reduce the risk of virus structural mutations. Based on application, the hospital infection therapeutics market has been segmented into Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders, and Other Hospital Infections. The pneumonia segment hold dominate the market share during the forecast period with significant growth rate, followed by surgical site infections, due to increase in incidence rate of respiratory infections among the aged population, comparatively above-average cost of treatment, and incidence of multidrug-resistant micro-organisms in ICU units. Hospital Infection Therapeutics Market Regional Analysis: Geographically, the hospital infection therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the hospital infection therapeutics market in 2018, due to improved healthcare awareness, high ratio of hospitals as compared to population of the region, increasing count of multidrug-resistant microbial pathogens and increase in aging population of the region. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period, owing to increased incidences of hospital infections and high demands of therapeutic drugs in emerging countries such as India and China. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are expected to impelling the market growth in this region over the forecast period. Hospital Infection Therapeutics Market Competitive landscape Major Key players operating in this market are Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Bayer AG, and Sanofi S.A. Manufacturers in the hospital infection therapeutics are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present a comprehensive analysis of Hospital Infection Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Hospital Infection Therapeutics Market dynamics, structure by analyzing the market segments and project the Hospital Infection Therapeutics Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Hospital Infection Therapeutics Market make the report investor’s guide.

Scope of the Hospital Infection Therapeutics Market:

Hospital Infection Therapeutics Market, by Drugs Type:

• Antibiotics Drugs • Antifungal Drugs • Antiviral Drugs

Hospital Infection Therapeutics Market, by Application:

• Bloodstream Infections • Pneumonia • Surgical Site Infections • Urinary Tract Infections • Gastrointestinal Disorders • Other Hospital Infections

Hospital Infection Therapeutics Market, by Region:

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Hospital Infection Therapeutics Market, Major Players:

• Merck & Co., Inc. • Pfizer, Inc. • GlaxoSmithKline plc • AstraZeneca • Johnson & Johnson Services, Inc. • F. Hoffmann-La Roche Ltd. • Bayer AG • Allergan plc • Sanofi S.A. • Gilead Sciences, Inc. • Basilea Pharmaceutica Ltd. • Bristol-Myers Squibb Company • Actavis plc • Cubist Pharmaceuticals, Inc. Global Dental Chair Market

Table of Contents

Hospital Infection Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Hospital Infection Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Hospital Infection Therapeutics Market Analysis and Forecast 6.1. Global Hospital Infection Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Drugs Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type 7.4. Global Hospital Infection Therapeutics Market Size (US$ Bn) Forecast, by Drugs Type 7.5. Global Hospital Infection Therapeutics Market Analysis, by Drugs Type 7.6. Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Drugs Type 8. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Hospital Infection Therapeutics Market Value Share Analysis, by Application 8.4. Global Hospital Infection Therapeutics Market Size (US$ Bn) Forecast, by Application 8.5. Global Hospital Infection Therapeutics Market Analysis, by Application 8.6. Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Application 9. Global Hospital Infection Therapeutics Market Analysis, by Region 9.1. Global Hospital Infection Therapeutics Market Value Share Analysis, by Region 9.2. Global Hospital Infection Therapeutics Market Size (US$ Bn) Forecast, by Region 9.3. Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Region 10. North America Hospital Infection Therapeutics Market Analysis 10.1. Key Findings 10.2. North America Hospital Infection Therapeutics Market Overview 10.3. North America Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type 10.4. North America Hospital Infection Therapeutics Market Forecast, by Drugs Type 10.4.1. Antibiotics Drugs 10.4.2. Antifungal Drugs 10.4.3. Antiviral Drugs 10.5. North America Hospital Infection Therapeutics Market Value Share Analysis, by Application 10.6. North America Hospital Infection Therapeutics Market Forecast, by Application 10.6.1. Bloodstream Infections 10.6.2. Pneumonia 10.6.3. Surgical Site Infections 10.6.4. Urinary Tract Infections 10.6.5. Gastrointestinal Disorders 10.6.6. Other Hospital Infections 10.7. North America Hospital Infection Therapeutics Market Value Share Analysis, by Country 10.8. North America Hospital Infection Therapeutics Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Hospital Infection Therapeutics Market Analysis, by Country 10.10. U.S. Hospital Infection Therapeutics Market Forecast, by Drugs Type 10.10.1. Antibiotics Drugs 10.10.2. Antifungal Drugs 10.10.3. Antiviral Drugs 10.11. U.S. Hospital Infection Therapeutics Market Forecast, by Application 10.11.1. Bloodstream Infections 10.11.2. Pneumonia 10.11.3. Surgical Site Infections 10.11.4. Urinary Tract Infections 10.11.5. Gastrointestinal Disorders 10.11.6. Other Hospital Infections 10.12. Canada Hospital Infection Therapeutics Market Forecast, by Drugs Type 10.12.1. Antibiotics Drugs 10.12.2. Antifungal Drugs 10.12.3. Antiviral Drugs 10.13. Canada Hospital Infection Therapeutics Market Forecast, by Application 10.13.1. Bloodstream Infections 10.13.2. Pneumonia 10.13.3. Surgical Site Infections 10.13.4. Urinary Tract Infections 10.13.5. Gastrointestinal Disorders 10.13.6. Other Hospital Infections 10.14. North America Hospital Infection Therapeutics Market Attractiveness Analysis 10.14.1. By Drugs Type 10.14.2. By Application 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Hospital Infection Therapeutics Market Analysis 11.1. Key Findings 11.2. Europe Hospital Infection Therapeutics Market Overview 11.3. Europe Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type 11.4. Europe Hospital Infection Therapeutics Market Forecast, by Drugs Type 11.4.1. Antibiotics Drugs 11.4.2. Antifungal Drugs 11.4.3. Antiviral Drugs 11.5. Europe Hospital Infection Therapeutics Market Value Share Analysis, by Application 11.6. Europe Hospital Infection Therapeutics Market Forecast, by Application 11.6.1. Bloodstream Infections 11.6.2. Pneumonia 11.6.3. Surgical Site Infections 11.6.4. Urinary Tract Infections 11.6.5. Gastrointestinal Disorders 11.6.6. Other Hospital Infections 11.7. Europe Hospital Infection Therapeutics Market Value Share Analysis, by Country 11.8. Europe Hospital Infection Therapeutics Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Hospital Infection Therapeutics Market Analysis, by Country 11.10. Germany Hospital Infection Therapeutics Market Forecast, by Drugs Type 11.10.1. Antibiotics Drugs 11.10.2. Antifungal Drugs 11.10.3. Antiviral Drugs 11.11. Germany Hospital Infection Therapeutics Market Forecast, by Application 11.11.1. Bloodstream Infections 11.11.2. Pneumonia 11.11.3. Surgical Site Infections 11.11.4. Urinary Tract Infections 11.11.5. Gastrointestinal Disorders 11.11.6. Other Hospital Infections 11.12. U.K. Hospital Infection Therapeutics Market Forecast, by Drugs Type 11.12.1. Antibiotics Drugs 11.12.2. Antifungal Drugs 11.12.3. Antiviral Drugs 11.13. U.K. Hospital Infection Therapeutics Market Forecast, by Application 11.13.1. Bloodstream Infections 11.13.2. Pneumonia 11.13.3. Surgical Site Infections 11.13.4. Urinary Tract Infections 11.13.5. Gastrointestinal Disorders 11.13.6. Other Hospital Infections 11.14. France Hospital Infection Therapeutics Market Forecast, by Drugs Type 11.14.1. Antibiotics Drugs 11.14.2. Antifungal Drugs 11.14.3. Antiviral Drugs 11.15. France Hospital Infection Therapeutics Market Forecast, by Application 11.15.1. Bloodstream Infections 11.15.2. Pneumonia 11.15.3. Surgical Site Infections 11.15.4. Urinary Tract Infections 11.15.5. Gastrointestinal Disorders 11.15.6. Other Hospital Infections 11.16. Italy Hospital Infection Therapeutics Market Forecast, by Drugs Type 11.16.1. Antibiotics Drugs 11.16.2. Antifungal Drugs 11.16.3. Antiviral Drugs 11.17. Italy Hospital Infection Therapeutics Market Forecast, by Application 11.17.1. Bloodstream Infections 11.17.2. Pneumonia 11.17.3. Surgical Site Infections 11.17.4. Urinary Tract Infections 11.17.5. Gastrointestinal Disorders 11.17.6. Other Hospital Infections 11.18. Spain Hospital Infection Therapeutics Market Forecast, by Drugs Type 11.18.1. Antibiotics Drugs 11.18.2. Antifungal Drugs 11.18.3. Antiviral Drugs 11.19. Spain Hospital Infection Therapeutics Market Forecast, by Application 11.19.1. Bloodstream Infections 11.19.2. Pneumonia 11.19.3. Surgical Site Infections 11.19.4. Urinary Tract Infections 11.19.5. Gastrointestinal Disorders 11.19.6. Other Hospital Infections 11.20. Rest of Europe Hospital Infection Therapeutics Market Forecast, by Drugs Type 11.20.1. Antibiotics Drugs 11.20.2. Antifungal Drugs 11.20.3. Antiviral Drugs 11.21. Rest of Europe Hospital Infection Therapeutics Market Forecast, by Application 11.21.1. Bloodstream Infections 11.21.2. Pneumonia 11.21.3. Surgical Site Infections 11.21.4. Urinary Tract Infections 11.21.5. Gastrointestinal Disorders 11.21.6. Other Hospital Infections 11.22. Europe Hospital Infection Therapeutics Market Attractiveness Analysis 11.22.1. By Drugs Type 11.22.2. By Application 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Hospital Infection Therapeutics Market Analysis 12.1. Key Findings 12.2. Asia Pacific Hospital Infection Therapeutics Market Overview 12.3. Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type 12.4. Asia Pacific Hospital Infection Therapeutics Market Forecast, by Drugs Type 12.4.1. Antibiotics Drugs 12.4.2. Antifungal Drugs 12.4.3. Antiviral Drugs 12.5. Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Application 12.6. Asia Pacific Hospital Infection Therapeutics Market Forecast, by Application 12.6.1. Bloodstream Infections 12.6.2. Pneumonia 12.6.3. Surgical Site Infections 12.6.4. Urinary Tract Infections 12.6.5. Gastrointestinal Disorders 12.6.6. Other Hospital Infections 12.7. Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Country 12.8. Asia Pacific Hospital Infection Therapeutics Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Hospital Infection Therapeutics Market Analysis, by Country 12.10. China Hospital Infection Therapeutics Market Forecast, by Drugs Type 12.10.1. Antibiotics Drugs 12.10.2. Antifungal Drugs 12.10.3. Antiviral Drugs 12.11. China Hospital Infection Therapeutics Market Forecast, by Application 12.11.1. Bloodstream Infections 12.11.2. Pneumonia 12.11.3. Surgical Site Infections 12.11.4. Urinary Tract Infections 12.11.5. Gastrointestinal Disorders 12.11.6. Other Hospital Infections 12.12. India Hospital Infection Therapeutics Market Forecast, by Drugs Type 12.12.1. Antibiotics Drugs 12.12.2. Antifungal Drugs 12.12.3. Antiviral Drugs 12.13. India Hospital Infection Therapeutics Market Forecast, by Application 12.13.1. Bloodstream Infections 12.13.2. Pneumonia 12.13.3. Surgical Site Infections 12.13.4. Urinary Tract Infections 12.13.5. Gastrointestinal Disorders 12.13.6. Other Hospital Infections 12.14. Japan Hospital Infection Therapeutics Market Forecast, by Drugs Type 12.14.1. Antibiotics Drugs 12.14.2. Antifungal Drugs 12.14.3. Antiviral Drugs 12.15. Japan Hospital Infection Therapeutics Market Forecast, by Application 12.15.1. Bloodstream Infections 12.15.2. Pneumonia 12.15.3. Surgical Site Infections 12.15.4. Urinary Tract Infections 12.15.5. Gastrointestinal Disorders 12.15.6. Other Hospital Infections 12.16. ASEAN Hospital Infection Therapeutics Market Forecast, by Drugs Type 12.16.1. Antibiotics Drugs 12.16.2. Antifungal Drugs 12.16.3. Antiviral Drugs 12.17. ASEAN Hospital Infection Therapeutics Market Forecast, by Application 12.17.1. Bloodstream Infections 12.17.2. Pneumonia 12.17.3. Surgical Site Infections 12.17.4. Urinary Tract Infections 12.17.5. Gastrointestinal Disorders 12.17.6. Other Hospital Infections 12.18. Rest of Asia Pacific Hospital Infection Therapeutics Market Forecast, by Drugs Type 12.18.1. Antibiotics Drugs 12.18.2. Antifungal Drugs 12.18.3. Antiviral Drugs 12.19. Rest of Asia Pacific Hospital Infection Therapeutics Market Forecast, by Application 12.19.1. Bloodstream Infections 12.19.2. Pneumonia 12.19.3. Surgical Site Infections 12.19.4. Urinary Tract Infections 12.19.5. Gastrointestinal Disorders 12.19.6. Other Hospital Infections 12.20. Asia Pacific Hospital Infection Therapeutics Market Attractiveness Analysis 12.20.1. By Drugs Type 12.20.2. By Application 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Hospital Infection Therapeutics Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Hospital Infection Therapeutics Market Overview 13.3. Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type 13.4. Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Drugs Type 13.4.1. Antibiotics Drugs 13.4.2. Antifungal Drugs 13.4.3. Antiviral Drugs 13.5. Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Application 13.6. Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Application 13.6.1. Bloodstream Infections 13.6.2. Pneumonia 13.6.3. Surgical Site Infections 13.6.4. Urinary Tract Infections 13.6.5. Gastrointestinal Disorders 13.6.6. Other Hospital Infections 13.7. Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Country 13.8. Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Hospital Infection Therapeutics Market Analysis, by Country 13.10. GCC Hospital Infection Therapeutics Market Forecast, by Drugs Type 13.10.1. Antibiotics Drugs 13.10.2. Antifungal Drugs 13.10.3. Antiviral Drugs 13.11. GCC Hospital Infection Therapeutics Market Forecast, by Application 13.11.1. Bloodstream Infections 13.11.2. Pneumonia 13.11.3. Surgical Site Infections 13.11.4. Urinary Tract Infections 13.11.5. Gastrointestinal Disorders 13.11.6. Other Hospital Infections 13.12. South Africa Hospital Infection Therapeutics Market Forecast, by Drugs Type 13.12.1. Antibiotics Drugs 13.12.2. Antifungal Drugs 13.12.3. Antiviral Drugs 13.13. South Africa Hospital Infection Therapeutics Market Forecast, by Application 13.13.1. Bloodstream Infections 13.13.2. Pneumonia 13.13.3. Surgical Site Infections 13.13.4. Urinary Tract Infections 13.13.5. Gastrointestinal Disorders 13.13.6. Other Hospital Infections 13.14. Rest of Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Drugs Type 13.14.1. Antibiotics Drugs 13.14.2. Antifungal Drugs 13.14.3. Antiviral Drugs 13.15. Rest of Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Application 13.15.1. Bloodstream Infections 13.15.2. Pneumonia 13.15.3. Surgical Site Infections 13.15.4. Urinary Tract Infections 13.15.5. Gastrointestinal Disorders 13.15.6. Other Hospital Infections 13.16. Middle East & Africa Hospital Infection Therapeutics Market Attractiveness Analysis 13.16.1. By Drugs Type 13.16.2. By Application 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Hospital Infection Therapeutics Market Analysis 14.1. Key Findings 14.2. South America Hospital Infection Therapeutics Market Overview 14.3. South America Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type 14.4. South America Hospital Infection Therapeutics Market Forecast, by Drugs Type 14.4.1. Antibiotics Drugs 14.4.2. Antifungal Drugs 14.4.3. Antiviral Drugs 14.5. South America Hospital Infection Therapeutics Market Value Share Analysis, by Application 14.6. South America Hospital Infection Therapeutics Market Forecast, by Application 14.6.1. Bloodstream Infections 14.6.2. Pneumonia 14.6.3. Surgical Site Infections 14.6.4. Urinary Tract Infections 14.6.5. Gastrointestinal Disorders 14.6.6. Other Hospital Infections 14.7. South America Hospital Infection Therapeutics Market Value Share Analysis, by Country 14.8. South America Hospital Infection Therapeutics Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Hospital Infection Therapeutics Market Forecast, by Drugs Type 14.9.1. Antibiotics Drugs 14.9.2. Antifungal Drugs 14.9.3. Antiviral Drugs 14.10. Brazil Hospital Infection Therapeutics Market Forecast, by Application 14.10.1. Bloodstream Infections 14.10.2. Pneumonia 14.10.3. Surgical Site Infections 14.10.4. Urinary Tract Infections 14.10.5. Gastrointestinal Disorders 14.10.6. Other Hospital Infections 14.11. Mexico Hospital Infection Therapeutics Market Forecast, by Drugs Type 14.11.1. Antibiotics Drugs 14.11.2. Antifungal Drugs 14.11.3. Antiviral Drugs 14.12. Mexico Hospital Infection Therapeutics Market Forecast, by Application 14.12.1. Bloodstream Infections 14.12.2. Pneumonia 14.12.3. Surgical Site Infections 14.12.4. Urinary Tract Infections 14.12.5. Gastrointestinal Disorders 14.12.6. Other Hospital Infections 14.13. Rest of South America Hospital Infection Therapeutics Market Forecast, by Drugs Type 14.13.1. Antibiotics Drugs 14.13.2. Antifungal Drugs 14.13.3. Antiviral Drugs 14.14. Rest of South America Hospital Infection Therapeutics Market Forecast, by Application 14.14.1. Bloodstream Infections 14.14.2. Pneumonia 14.14.3. Surgical Site Infections 14.14.4. Urinary Tract Infections 14.14.5. Gastrointestinal Disorders 14.14.6. Other Hospital Infections 14.15. South America Hospital Infection Therapeutics Market Attractiveness Analysis 14.15.1. By Drugs Type 14.15.2. By Application 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Merck & Co., Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Pfizer, Inc. 15.3.3. GlaxoSmithKline plc 15.3.4. AstraZeneca 15.3.5. Johnson & Johnson Services, Inc. 15.3.6. F. Hoffmann-La Roche Ltd. 15.3.7. Bayer AG 15.3.8. Allergan plc 15.3.9. Sanofi S.A. 15.3.10. Gilead Sciences, Inc. 15.3.11. Basilea Pharmaceutica Ltd. 15.3.12. Bristol-Myers Squibb Company 15.3.13. Actavis plc 15.3.14. Cubist Pharmaceuticals, Inc. 16. Primary Key Insights

About This Report

Report ID39281
Published DateDec 2019
Contact Us
Call Now